UCSF, in collaboration with the Quantum Leap Healthcare Collaborative (QLHC) and the U.S. Food and Drug Administration (FDA), has developed the OneSource system to seamlessly integrate clinical care and research data.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Plenty of probiotic yogurts, pickles and kombuchas claim to boost our digestive health with armies of microbes, but some scientists have more ambitious therapeutic plans for the “bugs” that colonize us. They hope to leverage these microbes as living therapeutics for a range of health conditions, including ulcerative colitis, multiple sclerosis, eczema and asthma.
What kills most people who die from cancer is not the initial tumor. It’s the intolerable disease burden on the body that arises when tumor cells continually expand their numbers after spreading to different organs.